<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
    <journal-id journal-id-type="iso-abbrev">Proc Natl Acad Sci U S A</journal-id>
    <journal-id journal-id-type="hwp">pnas</journal-id>
    <journal-id journal-id-type="publisher-id">PNAS</journal-id>
    <journal-title-group>
      <journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0027-8424</issn>
    <issn pub-type="epub">1091-6490</issn>
    <publisher>
      <publisher-name>National Academy of Sciences</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8325244</article-id>
    <article-id pub-id-type="pmid">34282017</article-id>
    <article-id pub-id-type="publisher-id">202102344</article-id>
    <article-id pub-id-type="doi">10.1073/pnas.2102344118</article-id>
    <article-categories>
      <subj-group subj-group-type="hwp-journal-coll">
        <subject>435</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Biological Sciences</subject>
        <subj-group>
          <subject>Systems Biology</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Genome-scale metabolic network reconstruction of model animals as a platform for translational research</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7475-0136</contrib-id>
        <name>
          <surname>Wang</surname>
          <given-names>Hao</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8567-5960</contrib-id>
        <name>
          <surname>Robinson</surname>
          <given-names>Jonathan L.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9788-2019</contrib-id>
        <name>
          <surname>Kocabas</surname>
          <given-names>Pinar</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5072-2659</contrib-id>
        <name>
          <surname>Gustafsson</surname>
          <given-names>Johan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7753-9042</contrib-id>
        <name>
          <surname>Anton</surname>
          <given-names>Mihail</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cholley</surname>
          <given-names>Pierre-Etienne</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huang</surname>
          <given-names>Shan</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gobom</surname>
          <given-names>Johan</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">
          <sup>d</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9190-2979</contrib-id>
        <name>
          <surname>Svensson</surname>
          <given-names>Thomas</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Uhlen</surname>
          <given-names>Mattias</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">
          <sup>e</sup>
        </xref>
        <xref rid="aff6" ref-type="aff">
          <sup>f</sup>
        </xref>
        <xref rid="aff7" ref-type="aff">
          <sup>g</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3930-4354</contrib-id>
        <name>
          <surname>Zetterberg</surname>
          <given-names>Henrik</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">
          <sup>d</sup>
        </xref>
        <xref rid="aff8" ref-type="aff">
          <sup>h</sup>
        </xref>
        <xref rid="aff9" ref-type="aff">
          <sup>i</sup>
        </xref>
        <xref rid="aff10" ref-type="aff">
          <sup>j</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9955-6003</contrib-id>
        <name>
          <surname>Nielsen</surname>
          <given-names>Jens</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff5" ref-type="aff">
          <sup>e</sup>
        </xref>
        <xref rid="aff11" ref-type="aff">
          <sup>k</sup>
        </xref>
        <xref rid="cor1" ref-type="corresp">
          <sup>1</sup>
        </xref>
      </contrib>
      <aff id="aff1"><sup>a</sup>Department of Biology and Biological Engineering, <institution>Chalmers University of Technology</institution>, SE-412 96 Gothenburg, <country>Sweden</country>;</aff>
      <aff id="aff2"><sup>b</sup>Department of Biology and Biological Engineering, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, <institution>Chalmers University of Technology</institution>, SE-412 96 Gothenburg, <country>Sweden</country>;</aff>
      <aff id="aff3"><sup>c</sup>Wallenberg Center for Molecular and Translational Medicine, <institution>University of Gothenburg</institution>, 405 30 Gothenburg, <country>Sweden</country>;</aff>
      <aff id="aff4"><sup>d</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, <institution>Sahlgrenska Academy at University of Gothenburg</institution>, 431 30 Mölndal, <country>Sweden</country>;</aff>
      <aff id="aff5"><sup>e</sup>Novo Nordisk Foundation Center for Biosustainability, <institution>Technical University of Denmark</institution>, 2800 Kgs. Lyngby, <country>Denmark</country>;</aff>
      <aff id="aff6"><sup>f</sup>Department of Protein Science, Science for Life Laboratory, <institution>KTH–Royal Institute of Technology</institution>, SE-100 44 Stockholm, <country>Sweden</country>;</aff>
      <aff id="aff7"><sup>g</sup>Wallenberg Center for Protein Research, <institution>KTH–Royal Institute of Technology</institution>, SE-100 44 Stockholm, <country>Sweden</country>;</aff>
      <aff id="aff8"><sup>h</sup>Clinical Neurochemistry Laboratory, <institution>Sahlgrenska University Hospital</institution>, 431 30 Mölndal, <country>Sweden</country>;</aff>
      <aff id="aff9"><sup>i</sup>Department of Neurodegenerative Disease, <institution>University College London Queen Square Institute of Neurology</institution>, London WC1E 6BT, <country>United Kingdom</country>;</aff>
      <aff id="aff10"><sup>j</sup>UK Dementia Research Institute, University College London, London WC1E 6BT, <country>United Kingdom</country>;</aff>
      <aff id="aff11"><sup>k</sup><institution>BioInnovation Institute</institution>, DK2200 Copenhagen, <country>Denmark</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>nielsenj@chalmers.se</email>.</corresp>
      <fn fn-type="edited-by">
        <p>Edited by Sang Yup Lee, Korea Advanced Institute of Science and Technology, Daejeon, South Korea, and approved June 15, 2021 (received for review February 5, 2021)</p>
      </fn>
      <fn fn-type="con">
        <p>Author contributions: H.W., P.K., J. Gustafsson, M.A., H.Z., and J.N. designed research; H.W., J.L.R., P.K., J. Gustafsson, M.A., P.-E.C., and S.H. performed research; T.S., M.U., and J.N. contributed new reagents/analytic tools; H.W., J.L.R., J. Gustafsson, M.A., P.-E.C., J. Gobom, H.Z., and J.N. analyzed data; and H.W., J.L.R., P.K., J. Gustafsson, M.A., H.Z., and J.N. wrote the paper.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>27</day>
      <month>7</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>19</day>
      <month>7</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>19</day>
      <month>7</month>
      <year>2021</year>
    </pub-date>
    <volume>118</volume>
    <issue>30</issue>
    <elocation-id>e2102344118</elocation-id>
    <permissions>
      <copyright-statement>Copyright © 2021 the Author(s). Published by PNAS.</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This open access article is distributed under <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>.</license-p>
      </license>
    </permissions>
    <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="pnas.202102344.pdf"/>
    <abstract abstract-type="executive-summary">
      <title>Significance</title>
      <p>Animal models and genome-scale metabolic models (GEMs) are two important tools for studying human diseases, but a proper integration of the two is lacking. To bridge them, we developed a reproducible and systematic framework by which the GEMs for major model animals are reconstructed and maintained. Due to the shared namespace, biological insights can be inferred from comparative analysis of the omics data from different animal models of the same disease. The drug targets and biomarkers derived from integrative metabolic analysis can thus be validated and translated to treatments and/or diagnostic methods. As an example, we demonstrated their utility in discovering potential biomarkers for early diagnosis of Alzheimer’s disease, where there is a lack of effective diagnostics and treatments.</p>
    </abstract>
    <abstract>
      <p>Genome-scale metabolic models (GEMs) are used extensively for analysis of mechanisms underlying human diseases and metabolic malfunctions. However, the lack of comprehensive and high-quality GEMs for model organisms restricts translational utilization of omics data accumulating from the use of various disease models. Here we present a unified platform of GEMs that covers five major model animals, including Mouse1 (<italic toggle="yes">Mus musculus</italic>), Rat1 (<italic toggle="yes">Rattus norvegicus</italic>), Zebrafish1 (<italic toggle="yes">Danio rerio</italic>), Fruitfly1 (<italic toggle="yes">Drosophila melanogaster</italic>), and Worm1 (<italic toggle="yes">Caenorhabditis elegans</italic>). These GEMs represent the most comprehensive coverage of the metabolic network by considering both orthology-based pathways and species-specific reactions. All GEMs can be interactively queried via the accompanying web portal Metabolic Atlas. Specifically, through integrative analysis of Mouse1 with RNA-sequencing data from brain tissues of transgenic mice we identified a coordinated up-regulation of lysosomal GM2 ganglioside and peptide degradation pathways which appears to be a signature metabolic alteration in Alzheimer’s disease (AD) mouse models with a phenotype of amyloid precursor protein overexpression. This metabolic shift was further validated with proteomics data from transgenic mice and cerebrospinal fluid samples from human patients. The elevated lysosomal enzymes thus hold potential to be used as a biomarker for early diagnosis of AD. Taken together, we foresee that this evolving open-source platform will serve as an important resource to facilitate the development of systems medicines and translational biomedical applications.</p>
    </abstract>
    <kwd-group>
      <kwd>genome-scale model</kwd>
      <kwd>animal model</kwd>
      <kwd>Alzheimer’s disease</kwd>
      <kwd>Aβ deposition</kwd>
      <kwd>translational medicine</kwd>
    </kwd-group>
    <funding-group>
      <award-group id="gs1">
        <funding-source id="sp1">Svenska Forskningsrådet Formas (Swedish Research Council Formas)<named-content content-type="funder-id">501100001862</named-content></funding-source>
        <award-id rid="sp1">(#2018-02532</award-id>
        <principal-award-recipient>Henrik Zetterberg</principal-award-recipient>
      </award-group>
      <award-group id="gs2">
        <funding-source id="sp2">EC | H2020 | H2020 Priority Excellent Science | H2020 European Research Council (ERC)<named-content content-type="funder-id">100010663</named-content></funding-source>
        <award-id rid="sp2">#681712</award-id>
        <principal-award-recipient>Henrik Zetterberg</principal-award-recipient>
      </award-group>
      <award-group id="gs3">
        <funding-source id="sp3">Swedish State Support for Clinical Research</funding-source>
        <award-id rid="sp3">#ALFGBG-720931</award-id>
        <principal-award-recipient>Henrik Zetterberg</principal-award-recipient>
      </award-group>
      <award-group id="gs4">
        <funding-source id="sp4">Alzheimer Drug Discovery Foundation</funding-source>
        <award-id rid="sp4">(#201809-2016862</award-id>
        <principal-award-recipient>Henrik Zetterberg</principal-award-recipient>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="9"/>
    </counts>
  </article-meta>
</front>
<body>
  <p content-type="flushleft">Animal models have long been utilized as a fundamental tool for translational research in recapitulating phenotypic syndromes, clarifying underlying mechanisms, and translating biomedical discoveries into effective clinical treatments for human disease (<xref rid="r1" ref-type="bibr">1</xref>). Small rodents, including mouse (<italic toggle="yes">Mus musculus</italic>) and rat (<italic toggle="yes">Rattus norvegicus</italic>), account for 90% of the tens of millions of animals used annually in medical research (<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r3" ref-type="bibr">3</xref>), and transgenic mice in particular are the most commonly used models for a plethora of human diseases including cancers, neurodegenerative dementia, diabetes, and many other metabolic disorders (<xref rid="r4" ref-type="bibr">4</xref>). In addition, with their unique anatomical and physiological features transgenic zebrafish (<italic toggle="yes">Danio rerio</italic>) and invertebrate models, such as the fruit fly (<italic toggle="yes">Drosophila melanogaster</italic>) and Nematoda worm (<italic toggle="yes">Caenorhabditis elegans</italic>), have been used for many years as inexpensive alternatives for studying human diseases through genetic manipulation of ortholog genes (<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref>). It is also important to note that nearly all the fundamental aspects of biology have been derived from the study of model organisms (<xref rid="r7" ref-type="bibr">7</xref>).</p>
  <p>A genome-scale metabolic model (GEM) is a mathematical representation of the metabolism for an organism and it provides extensive gene–reaction–metabolite connectivity via two matrices: the <italic toggle="yes">S</italic> matrix for associating metabolites to reactions and the <italic toggle="yes">rxnGeneMat</italic> matrix associating reactions to corresponding enzymes and genes (<xref rid="r8" ref-type="bibr">8</xref>). Given that many human diseases, including cancer, type II diabetes, and many liver- and pancreas-related diseases can be attributed to metabolic disorders (<xref rid="r9" ref-type="bibr">9</xref>), human GEMs have been used to describe the metabolic conditions of specific tissues and cell types at the systems level with the integration of omics data (<xref rid="r10" ref-type="bibr">10</xref><xref rid="r11" ref-type="bibr"/><xref rid="r12" ref-type="bibr"/>–<xref rid="r13" ref-type="bibr">13</xref>). For the purpose of clarity, henceforth “GEM” is used here to refer to a computational metabolic model, and “model” refers to a transgenic animal developed for studying human disease.</p>
  <p>The use of animal models together with GEMs poses an attractive approach to studying human disease. For example, mouse GEMs have previously been applied to investigate the influences of gut microbiota on host metabolism (<xref rid="r14" ref-type="bibr">14</xref>). To date, there have been a few existing GEMs for model animals, including MMR (<xref rid="r14" ref-type="bibr">14</xref>) and iMM1865 (<xref rid="r15" ref-type="bibr">15</xref>) for mouse, iRno (<xref rid="r16" ref-type="bibr">16</xref>) for rat, ZebraGEM (<xref rid="r17" ref-type="bibr">17</xref>, <xref rid="r18" ref-type="bibr">18</xref>) for zebrafish, and iCEL1273 and iCEL1314 for worm (<xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r20" ref-type="bibr">20</xref>). However, these GEMs have not been developed and publicly curated to the same extent as that of yeast (<xref rid="r21" ref-type="bibr">21</xref>) and human (<xref rid="r11" ref-type="bibr">11</xref>). Their limited coverage in metabolic pathways and incompatible nomenclatures impede cross-species validation of biological discoveries and translational applications from animal models to human patients.</p>
  <p>Recently, an open and version-controlled workflow has been introduced during the development of the most comprehensive yeast and human GEM, Yeast8 (<xref rid="r21" ref-type="bibr">21</xref>) and Human1 (<xref rid="r11" ref-type="bibr">11</xref>), respectively, which present high-quality templates to develop new GEMs in a systematic and reproducible manner. Databases such as MGD (<xref rid="r22" ref-type="bibr">22</xref>), FlyBase (<xref rid="r23" ref-type="bibr">23</xref>), ZFIN (<xref rid="r24" ref-type="bibr">24</xref>), and WormBase (<xref rid="r25" ref-type="bibr">25</xref>) that provide organism-specific annotation and human orthologs have been recently integrated into a centralized portal, the Alliance of Genome Resources (<xref rid="r26" ref-type="bibr">26</xref>), for consistent annotation and curation of gene ontology in relation to the human counterparts. Through channeling these reliable data sources we here present a unified GEM platform for mouse, rat, zebrafish, fruit fly, and worm. The derived GEMs (Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1, respectively) were reconstructed from a robust modeling pipeline that combines both the orthology-based metabolic network and species-specific pathways. To validate this approach, we conducted an extensive GEM comparison and gene essentiality analysis using available experimental data and demonstrated that our GEMs generally outperform the previous ones. We also showcased the usefulness of Mouse1 in systems medicine discovery by performing integrative analysis of omics data from mouse models of Alzheimer’s disease (AD). We are confident that this versatile GEM platform covering all major model animals will greatly enhance the utilization of omics data from disease models in facilitating translational studies.</p>
  <sec sec-type="results" id="s1">
    <title>Results</title>
    <sec id="s2">
      <title>GEM Reconstruction, Exploration, and Curation for Model Animals.</title>
      <p>We developed a pipeline that combines various reliable data sources and generates a coherent collection of GEMs for major model animals, including mouse (<italic toggle="yes">M. musculus</italic>), rat (<italic toggle="yes">R. norvegicus</italic>), zebrafish (<italic toggle="yes">D. rerio</italic>), fruit fly (<italic toggle="yes">D. melanogaster</italic>), and Nematoda worm (<italic toggle="yes">C. elegans</italic>) (<xref rid="fig01" ref-type="fig">Fig. 1</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1</ext-link>). In this pipeline, the open-curated generic human GEM, Human1 (<xref rid="r11" ref-type="bibr">11</xref>), was used as a template. The well-annotated orthologs and paralogs associated from human to the five model organisms, as well as evaluating features <italic toggle="yes">bestForward</italic>, <italic toggle="yes">bestReverse</italic>, and <italic toggle="yes">methodCount</italic> (the number of different methods used in determining the orthologs), were retrieved from the Alliance Genomes databases using the stringent criteria provided (<xref rid="r26" ref-type="bibr">26</xref>). All one-to-one pairs were kept, while the one-to-multiple pairs were filtered with the following criteria: 1) exclude the pairs that are neither <italic toggle="yes">bestforward</italic> nor <italic toggle="yes">bestReverse</italic> and 2) only keep the pairs that are both the best froward and reverse hits. If steps 1 and 2 exclude all hits for a query gene, then we retrieved and kept the ortholog pair(s) with the highest <italic toggle="yes">methodCount</italic>. Using the RAVEN toolbox (<xref rid="r27" ref-type="bibr">27</xref>), the species-specific reactions and metabolites for each animal were extracted from the KEGG (Kyoto Encyclopedia of Genes and Genomes) database and manually inspected for integration (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic></ext-link>). Here, we report the first releases of these simulation-ready animal GEMs as Mouse1, Rat1, Zebrafish1, Fruitfly1 and Worm1, respectively (<xref rid="fig01" ref-type="fig">Fig. 1</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S1</ext-link>).</p>
      <fig position="float" fig-type="featured" id="fig01">
        <label>Fig. 1.</label>
        <caption>
          <p>Genome-scale metabolic modeling for model animals. A reconstruction approach of combining (<italic toggle="yes">A</italic>) ortholog-GEMs derived from the Human1 template and (<italic toggle="yes">B</italic>) species-specific metabolic networks extracted from the KEGG database by the RAVEN package was used to obtain (<italic toggle="yes">C</italic>) the model animal GEMs that were deposited on GitHub according to the standard-GEM scheme (<xref rid="r28" ref-type="bibr">28</xref>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118fig01" id="gra1" position="float"/>
      </fig>
      <p>These new GEMs were integrated into the accompanying web portal Metabolic Atlas (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://metabolicatlas.org/" ext-link-type="uri" xlink:show="new">https://metabolicatlas.org/</ext-link>), which allows for interactive exploration and cross-species comparison of the GEMs through the GEM Browser, a tabular interface; the Map Viewer, a collection of manually curated two-dimensional maps and automated three-dimensional maps; and the Interaction Partners tool, a network view of gene-metabolite associations. Furthermore, the relational database (PostgreSQL) powering the Metabolic Atlas portal was replaced by a graph implementation (Neo4j), enabling new features such as GEM comparison via external identifiers. These improvements are released as Metabolic Atlas 2.0, which is open-source with the running website, graph database integration, upgraded three-dimensional viewer, and all data files publicly available (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic></ext-link>).</p>
      <p>To facilitate open curation and continuous integration of biochemical knowledge from the research community, these GEMs are tightly integrated with GitHub (see <xref rid="s10" ref-type="sec"><italic toggle="yes">Data Availability</italic></xref>) in complying with the “standard-GEM” specifications (<xref rid="r28" ref-type="bibr">28</xref>), which defines a set of requirements and recommendations for versioning GEMs and structuring Git-based repositories.</p>
    </sec>
    <sec id="s3">
      <title>GEM Comparison, Evaluation, and Validation.</title>
      <p>As generated by a coherent pipeline in which all primary identifiers belong to the same namespace, the new generic GEMs can be compared under a consistent scheme of subsystems (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>). Despite the reduction in the total number of reactions, Worm1 contained new phenylpropanoid biosynthesis pathway reactions, and the hormone biosynthesis pathway in Fruitfly1 was augmented, after the integration of a species-specific metabolic network. Likewise, Mouse1 and Rat1 are capable of de novo synthesis of vitamin C (ascorbate), a metabolic feature retained in most rodent species but lost in humans (<xref rid="r29" ref-type="bibr">29</xref>). In addition, the primary identifiers of metabolites and reactions from the new GEMs were all provided with the MetaNetX identifiers (<xref rid="r30" ref-type="bibr">30</xref>) for convenient comparison and expansion.</p>
      <fig position="float" fig-type="figure" id="fig02">
        <label>Fig. 2.</label>
        <caption>
          <p>Systematic comparison and evaluation of generic model animal GEMs. (<italic toggle="yes">A</italic>) Significantly altered subsystems with deviated reaction content between the newly generated GEMs and Human1. The color indicates the percent difference in the number of reactions within each subsystem for a GEM compared to the mean number of reactions in that subsystem across all GEMs. Radar plots showing the comparison in the numbers of reactions, metabolites, genes, and enzyme complexes that have a GPR with “and” relation, as well as benchmarking MEMOTE scores between the GEMs for (<italic toggle="yes">B</italic>) mouse, (<italic toggle="yes">C</italic>) rat, (<italic toggle="yes">D</italic>) zebrafish, (<italic toggle="yes">E</italic>) fruit fly, and (<italic toggle="yes">F</italic>) worm. (<italic toggle="yes">G</italic>) Evaluation of gene essentiality prediction performance among GEMs of mouse, fruit fly, and worm using the MCC, which scores the relative amount of true and false positive and negative predictions of gene essentiality.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118fig02" id="gra2" position="float"/>
      </fig>
      <p>To validate these newly developed GEMs, we conducted a systematic comparison with existing GEMs of the same species (<xref rid="fig02" ref-type="fig">Fig. 2</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S1</ext-link>). For each species, the newly generated GEMs obtained substantially expanded coverage in metabolic components of genes, reactions, and metabolites, as well as extended complex-subunit information (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">B–F</italic></xref>). An exception was the GEM BMID000000141998, which was produced from a fully automatic pipeline and included more genes and metabolites, but the quality of automatically generated GEMs is generally low due to lack of curation (<xref rid="r31" ref-type="bibr">31</xref>).</p>
      <p>The quality of a GEM is often evaluated by predicting genes that are essential to the viability of the organism and comparing the predictions with experimental data. To validate our animal GEM reconstruction pipeline, a gene essentiality analysis was conducted for each species by comparing the predictive performance of new and previous GEMs (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">G</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S2</ext-link>). In this analysis, the genes for a given GEM were individually knocked out in silico to identify those that are essential for biomass formation (cell viability). The prediction results were then compared with gene essentiality data retrieved from the Online Gene Essentiality (OGEE) database (<xref rid="r32" ref-type="bibr">32</xref>) to quantify the number of true and false positives and negatives. The Matthews correlation coefficient (MCC), a balanced metric of classification performance (<xref rid="r33" ref-type="bibr">33</xref>), was calculated for the GEMs of mouse, fruit fly, and worm, for which genome-scale experimental gene essentiality data were available (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S2</ext-link>). Mouse1 demonstrated a substantial improvement in essentiality predictions (MCC = 0.158) compared to 0.09 and 0.03 for iMM1865 and MMR, respectively. Fruitfly1 also showed a better predictive capacity than FlySilico, a simple GEM covering only central carbon, amino acid, lipid, and carbohydrate metabolism (<xref rid="r31" ref-type="bibr">31</xref>). The automatically generated GEM BMID000000141998 predicted all genes as nonessential and therefore had an undefined MCC value (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">G</italic></xref>). For the worm GEMs, Worm1 displayed improved prediction performance compared to iCEL1273 (<xref rid="r19" ref-type="bibr">19</xref>) and equivalent to the very recent iCEL1314, from which by incorporating the pathway for Ascaroside biosynthesis and transportation (<xref rid="r20" ref-type="bibr">20</xref>). This further highlights the importance of curation and more complete coverage of metabolism in obtaining systems-level insights.</p>
      <p>The MEMOTE scores (<xref rid="r34" ref-type="bibr">34</xref>), which were estimated from a series of tests on stoichiometric consistency, mass-balanced and blocked reactions, associated annotations, and so on, were used for benchmarking. The new GEMs outperformed the existing GEMs for each species with regard to MEMOTE scores (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">B–F</italic></xref>).</p>
    </sec>
    <sec id="s4">
      <title>Integrative Metabolic Analysis of AD Models Using Mouse1.</title>
      <p>Due to many attractive features (small and easy to handle, prolific breeder, and amenable to genetic manipulation) of mice and high genomic similarity to human, mouse models exist for a substantial number of diseases (<xref rid="r4" ref-type="bibr">4</xref>). They are extremely useful in studying the conditions for which patient samples and experiments are unfeasible or unethical to obtain (e.g., neurodegenerative diseases). To date, there are ∼200 different mouse models that have been developed for understanding the mechanism of AD (<xref rid="r35" ref-type="bibr">35</xref>), which is the most prevalent dementia affecting millions of people worldwide (<xref rid="r36" ref-type="bibr">36</xref>).</p>
      <p>To demonstrate the utility of the GEMs developed using our framework, Mouse1 was used to investigate different AD models through omics data integration and gene set analysis (<xref rid="fig03" ref-type="fig">Fig. 3</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Figs. S2–S6</ext-link>). Using a detailed search of the GEO database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic></ext-link>), a total of 11 high-quality RNA-sequencing (RNA-seq) datasets including both transgenic mice and wild-type controls with paired time points were selected from six representative AD models (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">A</italic> and <italic toggle="yes">B</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S3</ext-link>). There were four amyloid precursor protein (APP) overexpression models that recapitulate the major AD pathology (i.e., the formation of intracellular plaques and tangles containing aggregated amyloid β (Aβ) peptide and hyperphosphorylated tau protein), as well as two Trem2KO models with a deleted Trem2 gene that had complete or partial absence of the Aβ deposition phenotype. To make the figures simple and easy to understand, the models APPswe/PSEN1dE9 (line 85) and APPswe/PSEN1dE9 (C57BL6) that have identical genotype but use different mouse strains were merged and the sample GEO IDs were consistently provided for clarification. Next, we applied the task-driven integrative network inference algorithm (tINIT) (<xref rid="r37" ref-type="bibr">37</xref>) to generate tissue- and cell-type-specific GEMs, which combine the metabolic network determined by the RNA-seq data of metabolic genes and the essential reactions required for all cell types (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic></ext-link>). A structural comparison showed that the GEMs from APP overexpression models are more homogeneous than those from Trem2KO models, regardless of tissue source, gender, and age (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">C</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2</ext-link>). In contrast, the GEMs from Trem2KO model separated explicitly by cell types. GEMs from APP overexpression models were characterized by an enhanced coverage of pathways including cholesterol biosynthesis, beta oxidation of fatty acids, and amino acid metabolism but reduced coverage of biopterin metabolism (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3</ext-link>). In addition, de novo synthesis of asparagine, cystine, and cysteine and energy-associated functions were reduced in Trem2KO model GEMs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>). Interestingly, the GEMs of the hybrid model that was developed by crossing the Trem2KO and APPPS1 transgenic mice presented different metabolic features from both ascendants in reaction content (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">C</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2</ext-link>), subsystem coverage (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3</ext-link>), and metabolic task performance (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>). In summary, the comparison of these context-specific GEMs revealed distinct metabolism between the neuronal cells of APP overexpression and Trem2KO models.</p>
      <fig position="float" fig-type="figure" id="fig03">
        <label>Fig. 3.</label>
        <caption>
          <p>RNA-seq data integration and gene set analysis using Mouse1. (<italic toggle="yes">A</italic>) Various AD models of transgenic mice have been developed to recapitulate the pathology of Aβ deposition and subsequent phenotypes of subsequent neuroinflammation and cognitive impairment. (<italic toggle="yes">B</italic>) RNA-seq datasets from transgenic and wild-type mice with paired time points were selected for studying the metabolic changes associated with AD progression. The colored symbols are used to depict the different datasets and their sampling time points in relation to the onset and progression of Aβ deposition, which is illustrated by a shaded background (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S3</ext-link>). (<italic toggle="yes">C</italic>) Structural comparison of tissue/cell type-specific GEMs using <italic toggle="yes">t</italic>-distributed stochastic neighbor embedding (tSNE) analysis. (<italic toggle="yes">D</italic>) Reporter metabolite gene set analysis using Mouse1. The log-transformed P<sub>enrich</sub> value quantifies the significance of substantially up- (in positive values) or down-regulated (in negative values) gene sets between diseased and normal conditions. Subcellular compartment is indicated in brackets, in which l, m, and c refer to lysosome, mitochondrion, and cytosol, respectively. *The full names of the CoA metabolites are (6Z,9Z,12Z,15Z)-octadecatetraenoyl-CoA, (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoyl-CoA, and (7Z)-octadecenoyl-CoA and (6Z,9Z)-octadecadienoyl-CoA, respectively.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118fig03" id="gra3" position="float"/>
      </fig>
      <p>Enrichment analysis conducted with various gene-set collections also showed distinct metabolic differences between APP overexpression and Trem2KO models (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S5</ext-link>). Among the APP overexpression models, substantial expression profile changes were observed along with Aβ deposition, including the up-regulation of pathways in apoptosis, signaling, cholesterol homeostasis, innate immune system, allograft rejection, inflammatory and interferon response, and a number of energy metabolism and neurogenerative diseases (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S5</ext-link>). To pinpoint the altered metabolic processes associated with Aβ deposition we performed comparative analysis of subsystems (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6</ext-link>) and reporter metabolite gene sets (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">D</italic></xref>). The oxidative phosphorylation, amino acid metabolism, fatty acid oxidation, and cholesterol metabolism were identified as prominently up-regulated during the progression of AD (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6</ext-link>). This is consistent with the down-regulation of mitochondrial metabolite gene sets associated with energy metabolism in the AD models before the onset of Aβ deposition (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">D</italic></xref>). The alteration patterns of these metabolic pathways were also consistent with that found in the previous enrichment analysis (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S5</ext-link>), as well as the tissue-specific GEM comparison (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">C</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3</ext-link>). With gene–reaction–metabolite connectivity of GEMs, gene sets associated with each metabolite can be obtained and subjected to enrichment analysis that may reveal insights into network level alterations of given expression data. Notably, the gene sets of reporter metabolites (GM2A, H+, Pi, H<sub>2</sub>O, ADP, and ATP) associated with lysosome (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S3</ext-link>) were uniformly enriched in the APP overexpression models after Aβ deposition but absent from the hybrid Trem2 KO (KOMP) × APPPS1 model (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">D</italic></xref>).</p>
    </sec>
    <sec id="s5">
      <title>Aβ Accumulation Activates Gene Expression in Lysosomal Pathways of GM2 Gangliosides and Peptide Degradation.</title>
      <p>By integrative analysis of reporter metabolite gene sets with Mouse1 we discovered an up-regulated GM2A-centric lysosomal subnetwork shared between APP overexpression models (<xref rid="fig04" ref-type="fig">Fig. 4</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S7</ext-link>). This subnetwork was not enriched in the data from Trem2KO models, as well as the conditions prior to Aβ plaque formation in APP overexpression models (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S8</ext-link>). It therefore appeared to be the signature response induced specifically by Aβ accumulation. By inspecting the expression pattern of the lysosomal genes across the collected AD models we confirmed their consistent up-regulation in APP overexpression models and only after the onset of Aβ deposition (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">A</italic></xref>). Within the APP models, a higher magnitude of fold change of lysosomal genes was observed in APPPS1 compared to APP23 and APPswe/PSEN1dE9. Among the four time points from the APP23 model data (GSE80465), the up-regulation of the lysosomal genes peaked at 18 mo, whereas they appeared to slightly decrease in a later stage at 24 mo. In contrast, only marginal changes were observed in the APPswe/PSEN1dE9 (line 85) model (GSE136861), which were sampled with four time points (2, 4, 5, and 6 mo) when Aβ plaques have not been formed in the brain of transgenic mice (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S3</ext-link>).</p>
      <fig position="float" fig-type="figure" id="fig04">
        <label>Fig. 4.</label>
        <caption>
          <p>Integrative analysis of reporter metabolite gene sets with Mouse1. The up-regulation of a GM2A-centric subnetwork in lysosome is identified as a signature response to in APP overexpression models: (<italic toggle="yes">A</italic>) APPPS1, (<italic toggle="yes">B</italic>) APPswe/PSEN1dE9, and (<italic toggle="yes">C</italic>) APP23. This subnetwork, indicated by a dashed box, was found to be the most significant and consistent metabolic change to Aβ deposition. The nodes depict significantly changed reporter metabolite gene sets (cutoff: <italic toggle="yes">P</italic> &lt; 0.002), each of which comprises all genes associated with reactions in which one metabolite is involved. The node color reflects directionality score that indicates the overall differential direction of the gene set, ranging from down- (blue) to up-regulation (red). The node sizes are proportional to the −log10p values of corresponding gene sets, and the edge width indicates the number of reactions shared by the metabolites. (<italic toggle="yes">D</italic>) The diagram depicts the lysosomal degradation pathways that were detected from the elevated mouse genes through integrative analysis.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118fig04" id="gra4" position="float"/>
      </fig>
      <fig position="float" fig-type="figure" id="fig05">
        <label>Fig. 5.</label>
        <caption>
          <p>Validation of elevated lysosomal enzymes at the RNA and protein level. (<italic toggle="yes">A</italic>) Log2 fold changes of lysosomal genes (<italic toggle="yes">Gm2a</italic>, <italic toggle="yes">Hexa</italic>, <italic toggle="yes">Hexb</italic>, <italic toggle="yes">Ctsb</italic>, <italic toggle="yes">Ctsc</italic>, <italic toggle="yes">Ctsd</italic>, <italic toggle="yes">Ctsf</italic>, <italic toggle="yes">Ctss</italic>, <italic toggle="yes">Ctsz</italic>, and <italic toggle="yes">Nme4</italic>) that are involved in GM2 ganglioside and peptide degradation. The data from each AD model are displayed in the order of sampling time, while the onset of Aβ deposition is indicated by a dashed red line. (<italic toggle="yes">B</italic>) Bar plot showing the number of significantly (<italic toggle="yes">P</italic> &lt; 0.05) up-regulated lysosomal enzymes from five APP overexpression mouse models (hAPP, hAPP/PS1, 5xFAD, ADLP<sup>APPPS1</sup>, and ADLP<sup>APT</sup>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S4</ext-link>). (<italic toggle="yes">C</italic>) Heat maps showing the fold changes of these significantly up-regulated lysosomal enzymes along AD progression.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118fig05" id="gra5" position="float"/>
      </fig>
    </sec>
    <sec id="s6">
      <title>Validation of Activated Lysosomal Degradation Pathways Using Proteomics Data from AD Models.</title>
      <p>To validate the activation of the lysosomal degradation pathways at the protein level we reanalyzed proteomics datasets obtained from brain tissues of another five APP overexpression models: hAPP, hAPP/PS1, 5xFAD, ADLP<sup>ADP</sup>, and ADLP<sup>APP/PS1</sup> (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">B</italic></xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S3</ext-link>). Despite the different methods of mass spectrometric detection and quantification, a concerted up-regulation of the candidate lysosomal digestive enzymes, except Nme4, was observed among the differentially expressed proteins between transgenic versus wild-type mice at different time points (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">C</italic></xref>). In 5xFAD, ADLP<sup>APT</sup>, and ADLP<sup>APP/PS1</sup> models, AD progression was clearly accompanied by an increase of these lysosomal proteins in fold changes compared to the wild-type conditions. This suggests the potential application of their corresponding human orthologs, such as CTSS, as biomarkers for early diagnosis.</p>
    </sec>
    <sec id="s7">
      <title>Investigation of Lysosomal Peptide Concentrations in Cerebrospinal Fluid Samples of AD Patients.</title>
      <p>Since our approach ensured a consistent namespace and nomenclature between Human1 and new animal GEMs, this enables convenient translation of results from animal model experiments to human validation. Consequently, we sought to investigate the expression levels of these lysosomal enzymes in human samples. By analyzing a dataset from a recent study that quantified 51 targeted peptides in the cerebrospinal fluid samples from AD patients and healthy controls (<xref rid="r38" ref-type="bibr">38</xref>), we found that peptides from GM2A, CTSB, and CTSD were significantly enriched in AD patients compared to those from healthy individuals (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S9</ext-link>), supporting the association of altered lysosomal function in AD patients.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s8">
    <title>Discussion</title>
    <p content-type="flushleft">In this study we presented a robust animal GEM development pipeline with which the most comprehensive GEMs (Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1) for five major model animals were generated and maintained (<xref rid="fig01" ref-type="fig">Fig. 1</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1</ext-link>). With significantly expanded coverage of metabolic components compared to previously reported GEMs (<xref rid="fig02" ref-type="fig">Fig. 2</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S1</ext-link>), these new GEMs collectively serve as a coherent platform allowing systematic integration of high-throughput omics data from a wealth of disease models. These GEMs, capturing both the orthology-based metabolic network and species-specific pathways (<xref rid="fig01" ref-type="fig">Fig. 1</xref>) that can be interactively queried through the accompanying web portal Metabolic Atlas (<xref rid="r11" ref-type="bibr">11</xref>), will evolve as a continuously expanding knowledgebase for the study of animal metabolism.</p>
    <p>We demonstrated a specific case of using Mouse1 through a systems biology approach with omics data integration (<xref rid="fig03" ref-type="fig">Fig. 3</xref>). There exists an abundance of rodent models developed by introducing AD risk genes (<xref rid="r35" ref-type="bibr">35</xref>) that include APP and presenilin 1 and 2 (PSEN1 and PSEN2), which have been determined to cause Aβ deposition in familial forms of AD (<xref rid="r39" ref-type="bibr">39</xref>), and other susceptible genes (e.g., TREM2) that were associated with sporadic AD (<xref rid="r40" ref-type="bibr">40</xref>, <xref rid="r41" ref-type="bibr">41</xref>). Both APP overexpression and Trem2KO models, as well as the hybrid one Trem2KO × APPPS1 (<xref rid="r42" ref-type="bibr">42</xref>), were investigated to evaluate their metabolic features in terms of the different genetic backgrounds (<xref rid="fig03" ref-type="fig">Fig. 3</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Figs. S2–S4</ext-link>). The illustration of model-specific changes revealed their distinct metabolism, supporting the claim that each model can only recapitulate partial AD pathologies (<xref rid="r43" ref-type="bibr">43</xref>). This further stresses the necessity of an integrative evaluation of different transgenic animals, and our GEM-based in silico analysis was shown to be very useful in characterizing various animal models of the same disease in their metabolic capacity and guiding downstream investigations toward targeted clinical application.</p>
    <p>Aβ plaque formation increases with age in both transgenic mice and AD patients (<xref rid="r6" ref-type="bibr">6</xref>), making APP overexpression models useful tools in elucidating the temporal development of AD in human brain (<xref rid="r35" ref-type="bibr">35</xref>). Assisted by the comprehensive coverage of metabolic genes in Mouse1, a subnetwork of lysosomal degradation pathways was identified as a signature response to Aβ deposition across the APP overexpression models (<xref rid="fig04" ref-type="fig">Fig. 4</xref> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S7</ext-link>). The lysosomal pathways appeared to be activated immediately with the onset of Aβ deposition and sustained throughout the progression of AD in transgenic mice (<xref rid="fig05" ref-type="fig">Fig. 5</xref>). The increased transcription and translation of individual lysosomal components were previously detected in brains of AD and other neurodegenerative disease patients (<xref rid="bib51" ref-type="bibr">44</xref>). This is consistent with the observation of reduced Aβ levels in the brain of transgenic mice after in vivo up-regulation of lysosomal activities (<xref rid="r44" ref-type="bibr">45</xref>). In particular, our findings address lysosomal genes hydrolyzing GM2 gangliosides and peptides (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">D</italic></xref>), whose homeostasis in neurons is essential for brain maintenance (<xref rid="bib52" ref-type="bibr">46</xref>). Gangliosides are abundant in brain tissue and constitute ∼10 to 12% of the lipid content in neuronal membranes (<xref rid="bib53" ref-type="bibr">47</xref>). The content and composition of gangliosides decrease dramatically during aging (<xref rid="bib54" ref-type="bibr">48</xref>). The <italic toggle="yes">GM2A</italic>, <italic toggle="yes">HEXA</italic>, and <italic toggle="yes">HEXB</italic> genes encode enzymes responsible for degradation of GM2 gangliosides, mutations obstructing this pathway induce neurodegenerative disorders, including Tay–Sachs disease, AB variant, and Sandhoff disease (<xref rid="bib55" ref-type="bibr">49</xref>). Similarly, cysteine cathepsins CtsB/L have been demonstrated as essential in lysosomal degradation of Aβ peptides in mouse embryonic fibroblasts (<xref rid="bib56" ref-type="bibr">50</xref>). In vitro screening also showed that CtsB and CtsL can proteolyze α-synuclein amyloid fibrils that are closely associated with neurodegeneration in parkinsonian disorders, while CtsD requires the assistance of anionic lipids for the hydrolysis (<xref rid="bib57" ref-type="bibr">51</xref>). Collectively, a strong correlation between AD and endolysosomal activities has been established with a growing number of studies. Previously, genetic deficiency of lysosomal genes was speculated as the cause of endolysosomal and autophagic dysfunction that subsequently drives AD progression (<xref rid="r45" ref-type="bibr">52</xref>). Using a systematic analysis of AD models with and without Aβ plaques, however, our results suggests that up-regulation of lysosomal degradation pathways occurs downstream of Aβ deposition, such that elevated expression of lysosomal genes is a result of AD pathogenesis rather than a cause. Also, lysosomal dysfunction appears to be involved as a cascading effect of Aβ deposition and worth continued exploration.</p>
    <p>Biomarkers for an early diagnosis are urgently needed for AD due to the lack of effective treatments (<xref rid="r46" ref-type="bibr">53</xref>). There are currently three well-established biomarkers of lower Aβ42 levels and higher levels of total and phosphorylated tau for AD diagnosis (<xref rid="r47" ref-type="bibr">54</xref>). By translating the metabolic alterations obtained from analyzing AD models with Mouse1 (<xref rid="fig05" ref-type="fig">Fig. 5</xref>), here we presented a collection of nine lysosomal enzymes as potential biomarkers, of which CSTD has been previously verified in cerebrospinal fluid (<xref rid="r48" ref-type="bibr">55</xref>) and plasma samples (<xref rid="r49" ref-type="bibr">56</xref>), while the others represent new candidates. Our statistical analysis showed that the peptides of CTSB, CTSD, and GM2A in cerebrospinal fluid samples of AD patients are significantly increased compared to those in healthy controls (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S9</ext-link>). In addition, the rapid elevation of expressed lysosomal genes following Aβ deposition in mouse models also suggests that these lysosomal enzymes may be up-regulated in the prodromal phase of AD (<xref rid="fig05" ref-type="fig">Fig. 5</xref>). This is in good agreement with the longitudinal analysis of plasma CSTD levels, which were sampled from the same patients at preclinical phase and after diagnosed as AD (with an interval of 1 to 10 y), and both were significantly elevated in comparison to that in healthy controls (<xref rid="r49" ref-type="bibr">56</xref>). Taken together, the presented lysosomal enzymes identified with altered expression by the approach of systems medicines constitute potential body fluid biomarkers that may be utilized for early-stage AD diagnosis.</p>
    <p>In summary, we presented tissue- and time-dependent variations of AD mice and reported candidate biomarkers through integrative analysis of omics data with animal GEMs. By associating gene expression changes to subsystem and metabolite levels, this study demonstrated how results from model organism can be translated to clinical implications in human. Next, it is expected that the discovered disease-specific patterns and biomarkers could be inspected with large-scale comparative analysis of human datasets and body fluid samples for further verification. For quantitative flux predictions, we suggest contextualizing (e.g., tINIT) these GEMs with omics data and/or using the GECKO enzyme-constraint framework (<xref rid="r50" ref-type="bibr">57</xref>). Along with the rapidly growing omics data, we are confident that the set of animal GEMs will be a valuable platform assisting translational studies toward developing clinical treatments for a wide range of human diseases.</p>
  </sec>
  <sec sec-type="materials|methods" id="s9">
    <title>Materials and Methods</title>
    <p content-type="flushleft">All the materials and methods are detailed in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic></ext-link>: generation, comparison, and evaluation of animal GEMs; development of Metabolic Atlas 2.0; RNA-seq data retrieval and differential expression analysis; gene set and network integrative analysis; proteomics data investigation; and statistical analyses. All GEM simulations were carried out in MATLAB using RAVEN toolbox (<xref rid="r27" ref-type="bibr">27</xref>) with the Gurobi solver (Gurobi Optimization, LLC).</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118.sapp.pdf" id="d64e1130" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118.sd01.xlsx" id="d64e1133" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118.sd02.xlsx" id="d64e1136" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118.sd03.xlsx" id="d64e1139" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnas.2102344118.sd04.xlsx" id="d64e1142" position="anchor"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>We thank Leif Väremo, Francesco Gatto, Sinisa Bratulic, Rasool Saghaleyni, Fariba Roshanzamir, and Xin Chen for valuable discussions. The computations were performed on resources provided by the Swedish National Infrastructure for Computing at C3SE. This work was supported by the Knut and Alice Wallenberg Foundation and the Chalmers Foundation. H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation (201809-2016862), and the UK Dementia Research Institute at University College London.</p>
  </ack>
  <fn-group>
    <fn fn-type="COI-statement">
      <p>The authors declare no competing interest.</p>
    </fn>
    <fn fn-type="other">
      <p>This article is a PNAS Direct Submission.</p>
    </fn>
    <fn fn-type="supplementary-material">
      <p>This article contains supporting information online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental" ext-link-type="uri" xlink:show="new">https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2102344118/-/DCSupplemental</ext-link>.</p>
    </fn>
  </fn-group>
  <sec sec-type="data-availability" id="s10">
    <title>Data Availability</title>
    <p>The GEMs for Mouse1, Rat1, Zebrafish1, Fruitfly1, and Worm1 are available on GitHub at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/SysBioChalmers/Mouse-GEM" ext-link-type="uri" xlink:show="new">https://github.com/SysBioChalmers/Mouse-GEM</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/SysBioChalmers/Rat-GEM" ext-link-type="uri" xlink:show="new">https://github.com/SysBioChalmers/Rat-GEM</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/SysBioChalmers/Zebrafish-GEM" ext-link-type="uri" xlink:show="new">https://github.com/SysBioChalmers/Zebrafish-GEM</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/SysBioChalmers/Fruitfly-GEM" ext-link-type="uri" xlink:show="new">https://github.com/SysBioChalmers/Fruitfly-GEM</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/SysBioChalmers/Worm-GEM" ext-link-type="uri" xlink:show="new">https://github.com/SysBioChalmers/Worm-GEM</ext-link>, respectively. The code for GEM development is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/SysBioChalmers/Human-GEM" ext-link-type="uri" xlink:show="new">https://github.com/SysBioChalmers/Human-GEM</ext-link>. The tissue- and cell-type-specific GEMs for transgenic mice and code for integrative analysis are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/SysBioChalmers/Mouse-GEM" ext-link-type="uri" xlink:show="new">https://github.com/SysBioChalmers/Mouse-GEM</ext-link>. All other data are available in supporting information.</p>
  </sec>
  <ref-list>
    <ref id="r1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. P.</given-names><surname>Beck</surname></string-name>, <string-name><given-names>D. K.</given-names><surname>Meyerholz</surname></string-name></person-group>, <article-title>Evolving challenges to model human diseases for translational research</article-title>. <source>Cell Tissue Res.</source><volume>380</volume>, <fpage>305</fpage>–<lpage>311</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32130478</pub-id></mixed-citation>
    </ref>
    <ref id="r2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. A.</given-names><surname>Phillips</surname></string-name><etal/></person-group>., <article-title>Why primate models matter</article-title>. <source>Am. J. Primatol.</source><volume>76</volume>, <fpage>801</fpage>–<lpage>827</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24723482</pub-id></mixed-citation>
    </ref>
    <ref id="r3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Daneshian</surname></string-name>, <string-name><given-names>F.</given-names><surname>Busquet</surname></string-name>, <string-name><given-names>T.</given-names><surname>Hartung</surname></string-name>, <string-name><given-names>M.</given-names><surname>Leist</surname></string-name></person-group>, <article-title>Animal use for science in Europe</article-title>. <source>ALTEX</source><volume>32</volume>, <fpage>261</fpage>–<lpage>274</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26536288</pub-id></mixed-citation>
    </ref>
    <ref id="r4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names><surname>Rosenthal</surname></string-name>, <string-name><given-names>S.</given-names><surname>Brown</surname></string-name></person-group>, <article-title>The mouse ascending: Perspectives for human-disease models</article-title>. <source>Nat. Cell Biol.</source><volume>9</volume>, <fpage>993</fpage>–<lpage>999</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17762889</pub-id></mixed-citation>
    </ref>
    <ref id="r5">
      <label>5</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><given-names>E. E.</given-names><surname>Davis</surname></string-name>, <string-name><given-names>N.</given-names><surname>Katsanis</surname></string-name></person-group>, <source>Zebrafish: A Model System to Study the Architecture of Human Genetic Disease</source> (<publisher-name>Elsevier</publisher-name>, <year>2017</year>).</mixed-citation>
    </ref>
    <ref id="r6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. M.</given-names><surname>Dawson</surname></string-name>, <string-name><given-names>T. E.</given-names><surname>Golde</surname></string-name>, <string-name><given-names>C.</given-names><surname>Lagier-Tourenne</surname></string-name></person-group>, <article-title>Animal models of neurodegenerative diseases</article-title>. <source>Nat. Neurosci.</source><volume>21</volume>, <fpage>1370</fpage>–<lpage>1379</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30250265</pub-id></mixed-citation>
    </ref>
    <ref id="r7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Fields</surname></string-name>, <string-name><given-names>M.</given-names><surname>Johnston</surname></string-name></person-group>, <article-title>Whither model organism research?</article-title><source>Science (80-.)</source><volume>307</volume>, <fpage>1885</fpage>–<lpage>1886</lpage> (<year>2005</year>).</mixed-citation>
    </ref>
    <ref id="r8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Nielsen</surname></string-name></person-group>, <article-title>Systems biology of metabolism</article-title>. <source>Annu. Rev. Biochem.</source><volume>86</volume>, <fpage>245</fpage>–<lpage>275</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28301739</pub-id></mixed-citation>
    </ref>
    <ref id="r9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Nielsen</surname></string-name></person-group>, <article-title>Systems biology of metabolism: A driver for developing personalized and precision medicine</article-title>. <source>Cell Metab.</source><volume>25</volume>, <fpage>572</fpage>–<lpage>579</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28273479</pub-id></mixed-citation>
    </ref>
    <ref id="r10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names><surname>Agren</surname></string-name><etal/></person-group>., <article-title>Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT</article-title>. <source>PLOS Comput. Biol.</source><volume>8</volume>, <fpage>e1002518</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22615553</pub-id></mixed-citation>
    </ref>
    <ref id="r11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. L.</given-names><surname>Robinson</surname></string-name><etal/></person-group>., <article-title>An atlas of human metabolism</article-title>. <source>Sci. Signal.</source><volume>13</volume>, <fpage>1</fpage>–<lpage>12</lpage> (<year>2020</year>).</mixed-citation>
    </ref>
    <ref id="r12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. E.</given-names><surname>Lewis</surname></string-name>, <string-name><given-names>A. M.</given-names><surname>Abdel-Haleem</surname></string-name></person-group>, <article-title>The evolution of genome-scale models of cancer metabolism</article-title>. <source>Front. Physiol.</source><volume>4</volume>, <fpage>237</fpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24027532</pub-id></mixed-citation>
    </ref>
    <ref id="r13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names><surname>Yizhak</surname></string-name>, <string-name><given-names>B.</given-names><surname>Chaneton</surname></string-name>, <string-name><given-names>E.</given-names><surname>Gottlieb</surname></string-name>, <string-name><given-names>E.</given-names><surname>Ruppin</surname></string-name></person-group>, <article-title>Modeling cancer metabolism on a genome scale</article-title>. <source>Mol. Syst. Biol.</source><volume>11</volume>, <fpage>817</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26130389</pub-id></mixed-citation>
    </ref>
    <ref id="r14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names><surname>Mardinoglu</surname></string-name><etal/></person-group>., <article-title>The gut microbiota modulates host amino acid and glutathione metabolism in mice</article-title>. <source>Mol. Syst. Biol.</source><volume>11</volume>, <fpage>834</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26475342</pub-id></mixed-citation>
    </ref>
    <ref id="r15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Khodaee</surname></string-name>, <string-name><given-names>Y.</given-names><surname>Asgari</surname></string-name>, <string-name><given-names>M.</given-names><surname>Totonchi</surname></string-name>, <string-name><given-names>M. H.</given-names><surname>Karimi-Jafari</surname></string-name></person-group>, <article-title>iMM1865: A new reconstruction of mouse genome-scale metabolic model</article-title>. <source>Sci. Rep.</source><volume>10</volume>, <fpage>6177</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32277147</pub-id></mixed-citation>
    </ref>
    <ref id="r16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. M.</given-names><surname>Blais</surname></string-name><etal/></person-group>., <article-title>Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions</article-title>. <source>Nat. Commun.</source><volume>8</volume>, <fpage>14250</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28176778</pub-id></mixed-citation>
    </ref>
    <ref id="r17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Bekaert</surname></string-name></person-group>, <article-title>Reconstruction of Danio rerio metabolic model accounting for subcellular compartmentalisation</article-title>. <source>PLoS One</source><volume>7</volume>, <fpage>e49903</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23166792</pub-id></mixed-citation>
    </ref>
    <ref id="r18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names><surname>van Steijn</surname></string-name>, <string-name><given-names>F. J.</given-names><surname>Verbeek</surname></string-name>, <string-name><given-names>H. P.</given-names><surname>Spaink</surname></string-name>, <string-name><given-names>R. M. H.</given-names><surname>Merks</surname></string-name></person-group>, <article-title>Predicting metabolism from gene expression in an improved whole-genome metabolic network model of <italic toggle="yes">Danio rerio</italic></article-title>. <source>Zebrafish</source><volume>16</volume>, <fpage>348</fpage>–<lpage>362</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31216234</pub-id></mixed-citation>
    </ref>
    <ref id="r19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. S.</given-names><surname>Yilmaz</surname></string-name>, <string-name><given-names>A. J. M.</given-names><surname>Walhout</surname></string-name></person-group>, <article-title>A <italic toggle="yes">Caenorhabditis elegans</italic> genome-scale metabolic network model</article-title>. <source>Cell Syst.</source><volume>2</volume>, <fpage>297</fpage>–<lpage>311</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27211857</pub-id></mixed-citation>
    </ref>
    <ref id="r20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. S.</given-names><surname>Yilmaz</surname></string-name><etal/></person-group>., <article-title>Modeling tissue-relevant <italic toggle="yes">Caenorhabditis elegans</italic> metabolism at network, pathway, reaction, and metabolite levels</article-title>. <source>Mol. Syst. Biol.</source><volume>16</volume>, <fpage>e9649</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33022146</pub-id></mixed-citation>
    </ref>
    <ref id="r21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names><surname>Lu</surname></string-name><etal/></person-group>., <article-title>A consensus <italic toggle="yes">S. cerevisiae</italic> metabolic model Yeast8 and its ecosystem for comprehensively probing cellular metabolism</article-title>. <source>Nat. Commun.</source><volume>10</volume>, <fpage>3586</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31395883</pub-id></mixed-citation>
    </ref>
    <ref id="r22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. J.</given-names><surname>Bult</surname></string-name><etal/></person-group>., <article-title>Mouse Genome Database (MGD) 2019</article-title>. <source>Nucleic Acids Res.</source><volume>47</volume> (<issue>D1</issue>), <fpage>D801</fpage>–<lpage>D806</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30407599</pub-id></mixed-citation>
    </ref>
    <ref id="r23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names><surname>Larkin</surname></string-name><etal/></person-group>., <article-title>FlyBase: Updates to the <italic toggle="yes">Drosophila melanogaster</italic> knowledge base</article-title>. <source>Nucleic Acids Res.</source><volume>49</volume>, <fpage>D899</fpage>–<lpage>D907</lpage> (<year>2020</year>).</mixed-citation>
    </ref>
    <ref id="r24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names><surname>Ruzicka</surname></string-name><etal/></person-group>., <article-title>The Zebrafish Information Network: New support for non-coding genes, richer Gene Ontology annotations and the Alliance of Genome Resources</article-title>. <source>Nucleic Acids Res.</source><volume>47</volume>, <fpage>D867</fpage>–<lpage>D873</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30407545</pub-id></mixed-citation>
    </ref>
    <ref id="r25">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. W.</given-names><surname>Harris</surname></string-name><etal/></person-group>., <article-title>WormBase: A modern model organism information resource</article-title>. <source>Nucleic Acids Res.</source><volume>48</volume>, <fpage>D762</fpage>–<lpage>D767</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31642470</pub-id></mixed-citation>
    </ref>
    <ref id="r26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Agapite</surname></string-name><etal/></person-group>., <article-title>Alliance of Genome Resources Portal: Unified model organism research platform</article-title>. <source>Nucleic Acids Res.</source><volume>48</volume>, <fpage>D650</fpage>–<lpage>D658</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31552413</pub-id></mixed-citation>
    </ref>
    <ref id="r27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names><surname>Wang</surname></string-name><etal/></person-group>., <article-title>RAVEN 2.0: A versatile toolbox for metabolic network reconstruction and a case study on Streptomyces coelicolor</article-title>. <source>PLOS Comput. Biol.</source><volume>14</volume>, <fpage>e1006541</fpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30335785</pub-id></mixed-citation>
    </ref>
    <ref id="r28">
      <label>28</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Anton</surname></string-name>, <string-name><surname>ulfliebal</surname></string-name>, <string-name><given-names>H.</given-names><surname>Wang</surname></string-name></person-group>, <comment>MetabolicAtlas/Standard-GEM: Standard-GEM 0.5 (Version 0.5, Zenodo, 2021)</comment>.</mixed-citation>
    </ref>
    <ref id="r29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Nishikimi</surname></string-name>, <string-name><given-names>T.</given-names><surname>Kawai</surname></string-name>, <string-name><given-names>K.</given-names><surname>Yagi</surname></string-name></person-group>, <article-title>Guinea pigs possess a highly mutated gene for L-gulono-γ-lactone oxidase, the key enzyme for L-ascorbic acid biosynthesis missing in this species</article-title>. <source>J. Biol. Chem.</source><volume>267</volume>, <fpage>21967</fpage>–<lpage>21972</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1400507</pub-id></mixed-citation>
    </ref>
    <ref id="r30">
      <label>30</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Moretti</surname></string-name><etal/></person-group>., <article-title>MetaNetX/MNXref—Reconciliation of metabolites and biochemical reactions to bring together genome-scale metabolic networks</article-title>. <source>Nucleic Acids Res.</source><volume>44</volume>, <fpage>D523</fpage>–<lpage>D526</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26527720</pub-id></mixed-citation>
    </ref>
    <ref id="r31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. W.</given-names><surname>Schönborn</surname></string-name>, <string-name><given-names>L.</given-names><surname>Jehrke</surname></string-name>, <string-name><given-names>T.</given-names><surname>Mettler-Altmann</surname></string-name>, <string-name><given-names>M.</given-names><surname>Beller</surname></string-name></person-group>, <article-title>FlySilico: Flux balance modeling of <italic toggle="yes">Drosophila</italic> larval growth and resource allocation</article-title>. <source>Sci. Rep.</source><volume>9</volume>, <fpage>17156</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31748517</pub-id></mixed-citation>
    </ref>
    <ref id="r32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W. H.</given-names><surname>Chen</surname></string-name>, <string-name><given-names>G.</given-names><surname>Lu</surname></string-name>, <string-name><given-names>X.</given-names><surname>Chen</surname></string-name>, <string-name><given-names>X. M.</given-names><surname>Zhao</surname></string-name>, <string-name><given-names>P.</given-names><surname>Bork</surname></string-name></person-group>, <article-title>OGEE v2: An update of the online gene essentiality database with special focus on differentially essential genes in human cancer cell lines</article-title>. <source>Nucleic Acids Res.</source><volume>45</volume>, <fpage>D940</fpage>–<lpage>D944</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">27799467</pub-id></mixed-citation>
    </ref>
    <ref id="r33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. W.</given-names><surname>Matthews</surname></string-name></person-group>, <article-title>Comparison of the predicted and observed secondary structure of T4 phage lysozyme</article-title>. <source>BBA - Protein Struct.</source><volume>405</volume>, <fpage>442</fpage>–<lpage>451</lpage> (<year>1975</year>).</mixed-citation>
    </ref>
    <ref id="r34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names><surname>Lieven</surname></string-name><etal/></person-group>., <article-title>MEMOTE for standardized genome-scale metabolic model testing</article-title>. <source>Nat. Biotechnol.</source><volume>38</volume>, <fpage>272</fpage>–<lpage>276</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32123384</pub-id></mixed-citation>
    </ref>
    <ref id="r35">
      <label>35</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><collab>ALZFORUM</collab></person-group>, <article-title>AD research models</article-title>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.alzforum.org/research-models" ext-link-type="uri">https://www.alzforum.org/research-models</ext-link>. Accessed 22 June 2020.</mixed-citation>
    </ref>
    <ref id="r36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names><surname>Nichols</surname></string-name><etal/></person-group>., <article-title>Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016</article-title>. <source>Lancet Neurol.</source><volume>18</volume>, <fpage>88</fpage>–<lpage>106</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30497964</pub-id></mixed-citation>
    </ref>
    <ref id="r37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names><surname>Agren</surname></string-name><etal/></person-group>., <article-title>Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling</article-title>. <source>Mol. Syst. Biol.</source><volume>10</volume>, <fpage>721</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24646661</pub-id></mixed-citation>
    </ref>
    <ref id="r38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Sjödin</surname></string-name><etal/></person-group>., <article-title>Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease</article-title>. <source>Alzheimers Res. Ther.</source><volume>11</volume>, <fpage>82</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31521194</pub-id></mixed-citation>
    </ref>
    <ref id="r39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. M.</given-names><surname>Bekris</surname></string-name>, <string-name><given-names>C. E.</given-names><surname>Yu</surname></string-name>, <string-name><given-names>T. D.</given-names><surname>Bird</surname></string-name>, <string-name><given-names>D. W.</given-names><surname>Tsuang</surname></string-name></person-group>, <article-title>Genetics of Alzheimer disease</article-title>. <source>J. Geriatr. Psychiatry Neurol.</source><volume>23</volume>, <fpage>213</fpage>–<lpage>227</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">21045163</pub-id></mixed-citation>
    </ref>
    <ref id="r40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names><surname>Jonsson</surname></string-name><etal/></person-group>., <article-title>Variant of TREM2 associated with the risk of Alzheimer’s disease</article-title>. <source>N. Engl. J. Med.</source><volume>368</volume>, <fpage>107</fpage>–<lpage>116</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23150908</pub-id></mixed-citation>
    </ref>
    <ref id="r41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names><surname>Guerreiro</surname></string-name><etal/></person-group>., <article-title>TREM2 variants in Alzheimer’s disease</article-title>. <source>N. Engl. J. Med.</source><volume>368</volume>, <fpage>117</fpage>–<lpage>127</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23150934</pub-id></mixed-citation>
    </ref>
    <ref id="r42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. R.</given-names><surname>Jay</surname></string-name><etal/></person-group>., <article-title>TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models</article-title>. <source>J. Exp. Med.</source><volume>212</volume>, <fpage>287</fpage>–<lpage>295</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25732305</pub-id></mixed-citation>
    </ref>
    <ref id="r43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Verheijen</surname></string-name>, <string-name><given-names>K.</given-names><surname>Sleegers</surname></string-name></person-group>, <article-title>Understanding Alzheimer disease at the interface between genetics and transcriptomics</article-title>. <source>Trends Genet.</source><volume>34</volume>, <fpage>434</fpage>–<lpage>447</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29573818</pub-id></mixed-citation>
    </ref>
    <ref id="bib51">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names><surname>Yamamoto</surname></string-name>, <string-name><given-names>Z.</given-names><surname>Yue</surname></string-name></person-group>, <article-title>Autophagy and its normal and pathogenic states in the brain</article-title>. <source>Annu. Rev. Neurosci.</source><volume>37</volume>, <fpage>55</fpage>–<lpage>78</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24821313</pub-id></mixed-citation>
    </ref>
    <ref id="r44">
      <label>45</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names><surname>Xiao</surname></string-name><etal/></person-group>., <article-title>Neuronal-targeted TFEB accelerates lysosomal degradation of app, reducing Aβ generation and amyloid plaque pathogenesis</article-title>. <source>J. Neurosci.</source><volume>35</volume>, <fpage>12137</fpage>–<lpage>12151</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26338325</pub-id></mixed-citation>
    </ref>
    <ref id="bib52">
      <label>46</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Frere</surname></string-name>, <string-name><given-names>I.</given-names><surname>Slutsky</surname></string-name></person-group>, <article-title>Alzheimer’s Disease: from firing instability to homeostasis network collapse</article-title>. <source>Neuron</source><volume>97</volume>, <fpage>32</fpage>–<lpage>58</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29301104</pub-id></mixed-citation>
    </ref>
    <ref id="bib53">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names><surname>Kolter</surname></string-name></person-group>, <article-title>Ganglioside Biochemistry</article-title>. <source>ISRN Biochem.</source>, <fpage>1</fpage>–<lpage>36</lpage> (<year>2012</year>).</mixed-citation>
    </ref>
    <ref id="bib54">
      <label>48</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names><surname>Segler-Stahl</surname></string-name>, <string-name><given-names>J. C.</given-names><surname>Webster</surname></string-name>, <string-name><given-names>E. G.</given-names><surname>Brunngraber</surname></string-name></person-group>, <article-title>Changes in the concentration and composition of human brain gangliosides with aging</article-title>. <source>Gerontology</source><volume>29</volume>, <fpage>161</fpage>–<lpage>168</lpage> (<year>1983</year>).<pub-id pub-id-type="pmid">6852543</pub-id></mixed-citation>
    </ref>
    <ref id="bib55">
      <label>49</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. B.</given-names><surname>Cachon-Gonzalez</surname></string-name>, <string-name><given-names>E.</given-names><surname>Zaccariotto</surname></string-name>, <string-name><given-names>T. M.</given-names><surname>Cox</surname></string-name></person-group>, <article-title>Genetics and therapies for GM2 gangliosidosis</article-title>. <source>Curr. Gene. Ther.</source><volume>18</volume>, <fpage>68</fpage>–<lpage>89</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29618308</pub-id></mixed-citation>
    </ref>
    <ref id="bib56">
      <label>50</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Cermak</surname></string-name><etal/></person-group>., <article-title>Loss of Cathepsin B and L leads to lysosomal dysfunction, NPC-Like cholesterol sequestration and accumulation of the key Alzheimer’s proteins</article-title>. <source>PLoS One</source><volume>11</volume>, <fpage>e0167428</fpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27902765</pub-id></mixed-citation>
    </ref>
    <ref id="bib57">
      <label>51</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. P.</given-names><surname>McGlinchey</surname></string-name>, <string-name><given-names>J. C.</given-names><surname>Lee</surname></string-name></person-group>, <article-title>Cysteine cathepsins are essential in lysosomal degradation of α-synuclein</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>112</volume>, <fpage>9322</fpage>–<lpage>9327</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26170293</pub-id></mixed-citation>
    </ref>
    <ref id="r45">
      <label>52</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. S.</given-names><surname>Whyte</surname></string-name>, <string-name><given-names>A. A.</given-names><surname>Lau</surname></string-name>, <string-name><given-names>K. M.</given-names><surname>Hemsley</surname></string-name>, <string-name><given-names>J. J.</given-names><surname>Hopwood</surname></string-name>, <string-name><given-names>T. J.</given-names><surname>Sargeant</surname></string-name></person-group>, <article-title>Endo-lysosomal and autophagic dysfunction: A driving factor in Alzheimer’s disease?</article-title><source>J. Neurochem.</source><volume>140</volume>, <fpage>703</fpage>–<lpage>717</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28027395</pub-id></mixed-citation>
    </ref>
    <ref id="r46">
      <label>53</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names><surname>Dolgin</surname></string-name></person-group>, <article-title>How to defeat dementia</article-title>. <source>Nature</source><volume>539</volume>, <fpage>156</fpage>–<lpage>158</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27830826</pub-id></mixed-citation>
    </ref>
    <ref id="r47">
      <label>54</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names><surname>Olsson</surname></string-name><etal/></person-group>., <article-title>CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis</article-title>. <source>Lancet Neurol.</source><volume>15</volume>, <fpage>673</fpage>–<lpage>684</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27068280</pub-id></mixed-citation>
    </ref>
    <ref id="r48">
      <label>55</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. L.</given-names><surname>Schwagerl</surname></string-name><etal/></person-group>., <article-title>Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease</article-title>. <source>J. Neurochem.</source><volume>64</volume>, <fpage>443</fpage>–<lpage>446</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">7798944</pub-id></mixed-citation>
    </ref>
    <ref id="r49">
      <label>56</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. J.</given-names><surname>Goetzl</surname></string-name><etal/></person-group>., <article-title>Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease</article-title>. <source>Neurology</source><volume>85</volume>, <fpage>40</fpage>–<lpage>47</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26062630</pub-id></mixed-citation>
    </ref>
    <ref id="r50">
      <label>57</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. J.</given-names><surname>Sánchez</surname></string-name><etal/></person-group>., <article-title>Improving the phenotype predictions of a yeast genome-scale metabolic model by incorporating enzymatic constraints</article-title>. <source>Mol. Syst. Biol.</source><volume>13</volume>, <fpage>935</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28779005</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
